Paclitaxel: a hope for advanced non-small cell lung cancer?

Bibliography

• LANDIS SH, MURRAY T, BOLDEN S et al: Cancer Statis-tics, 1998. CA Cancel Clin. (1998) 48:6–29.
   PubMed Web of Science ®Google Scholar
• GINSBERG RJ, VOKES EE, RABEN A: Non-small cell lung cancer. In: Cancer Principles and Practice of Oncology (2nd Edition). DeVita VT, Hellman S, Rosenberg SA (Eds.), Lippincott-Raven, Philadelphia, PA, USA (1997):863–878.
   Google Scholar
• BUNN PA, KELLY K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. (1998) 5:1087–1100.
   Google Scholar
• SOQUET PJ, CHAUVIN F, BOISSEL J et al.: Polychemo-therapy in advanced non-small cell lung cancer: a meta-analysis. Lancet (1993) 342:19–21.
   PubMedGoogle Scholar
• NON-SMALL CELL LUNG CANCER CO-OPERATIVE GROUP: Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• ••Important meta-analysis identifying survival gains fromcisplatin based chemotherapy in NSCLC.
   Google Scholar
• MARINO P, PAMPALLONA S, PREATORNI A et al.: versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest (1994) 106:861–865.
   PubMed Web of Science ®Google Scholar
• WANT MC, TAYLOR HL, WALL MG etal.: Plant antitumouragents VI: the isolation and structure of taxol, a novel antileukaemic and antitumour agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 893:2325–2327.
   Google Scholar
• SCHIFF PB, FANT J, HORWITZ SB: Promotion of microtu-bule assembly in vitro by taxol. Nature (1979) 22:665–667.
   Web of Science ®Google Scholar
• •Identification of the novel mechanism of cytotoxic action of paclitaxel.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: The clinical pharma-cology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. (1991) 52:35–84.
   PubMed Web of Science ®Google Scholar
• VERWEI J, CLAVEL M, CHEVALIER B: Paclitaxel (Taxol) and docetaxel (taxotere): not simply two of a kind. Ann. Oncol. (1994) 5:495–505.
   PubMed Web of Science ®Google Scholar
• SCHIFF P, HORWITZ SB: Taxol stabilises microtubulesin mouse fibroblast cells. Proc. Natl. Acad. Sci. USA (1980) 77:1561–1565.
   PubMed Web of Science ®Google Scholar
• DUSTIN P: Microtubules 2nd edition, Springer Verlag, Berlin, Germany, (1984).
   Google Scholar
• MILAS L, HUNTER NR, KURDOGLU B et al.: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumours treated with taxol. Cancer Chemother. Pharmacol. (1995) 35:297–303.
   PubMed Web of Science ®Google Scholar
• SETTER K, FELDMAN EJ, TRAGANOS F et al: Evaluation ofin vivo induction of apoptosis in patients with acute leukaemia treated on a Phase I study of paclitaxel. Leukaemia (1995) 9:1961–1983.
   PubMed Web of Science ®Google Scholar
• IRELAND CM., PITTMAN SM: Tubulin alterations in taxolinduced apoptosis parallel those observed with other drugs. Biochem. Pharmacol. (1995) 10:1491–1499.
   Web of Science ®Google Scholar
• TORRES K, HORWITZ SB: Mechanisms of Taxol inducedcell death are concentration dependent. Cancer Res. (1998) 58:3620–3626.
   PubMed Web of Science ®Google Scholar
• WOODS CM, ZHU J, MCQUENEY PA et al: Taxol inducedmitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. (1995) 1:506–526.
   PubMed Web of Science ®Google Scholar
• LIU Y, BHALLA K, HILL C, PRIEST DG: Evidence forinvolvement of tyrosine phosphorylation in taxol induced apoptosis in a human ovarian cancer cell line. Biochem. Pharmacol. (1994) 48:1265–1272.
   PubMed Web of Science ®Google Scholar
• PONNATHPUR V, IBRADO AM, REED JC et al.: Effects ofmodulators of protein kinases on taxol induced apoptosis of human leukaemic cells possessing disparate levels of p26 BCL-2 protein. Clin. Cancer. Res. (1995) 1:1399–1406.
   PubMed Web of Science ®Google Scholar
• MILROSS CG, MASON KA, HUNTER NR et al.: Relationshipof mitotic arrest and apoptosis to antitumour effect of paclitaxel. J. Natl. Cancer Inst. (1996) 88:1308–1314.
   PubMed Web of Science ®Google Scholar
• LONGNECKER SM, DONEHOWER RC, CATES AE et al.:High performance liquid chromatographic assay for taxol (NSC 125973) in human plasma and urine: pharmacokinetics in a Phase I trial. Cancer Treat. Rep. (1986) 71:53–59.
   Google Scholar
• WIERNIK PH, SCWARTZ EL, EINZIG A et al.: Phase I trialof taxol as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. (1987) 5:1232–1239.
   PubMed Web of Science ®Google Scholar
• KEUNG ACF, KAUL S, PINEDO HM et al: Pharmacoki-netics of taxol given by 3-hour or 24-hour infusion to patients with ovarian cancer. Proc. Am. Soc. Clin. Oncol. (1993) 12:120.
   Google Scholar
• KEARNS CM: Pharmacokinetics of the taxanes. Pharma-cotherapy (1997) 17:105–109.
   Google Scholar
• MAIER-LENTZ H, HAUNS B, HAERING B et al: Phase Istudy of paclitaxel administered as a 1 h infusion: toxicity and pharmacokinetics. Semin. Oncol. (1997) 24 (Suppl. 19) :16–19.
   Google Scholar
• CHAO Y, CHAN WK, BIRKHOFER MJ et al.: Phase II andpharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma. Br. J. Cancer (1998) 78:34–39.
   PubMed Web of Science ®Google Scholar
• VENOOK AP, EGORIN MJ, ROSNER GL et al.: Phase I andpharmacokinetic trial of paclitaxel in patients with hepatic dysfunction:Cancer and Leukaemia Group B 9264.j Clin. Oncol. (1998) 16:1811–1819.
   Google Scholar
• CHANG AY, KIM K, GLICK J et al.: Phase II study of taxol,mebarone and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst. (1993) 85:388–394.
   PubMed Web of Science ®Google Scholar
• •Along with reference 29 the first Phase II data identifying the antitumour activity of paclitaxel in patients with advanced NSCLC.
   Google Scholar
• MURPHY WK, FOSSELLA F, WINN RJ et al.: Phase II study Taxol in patients with untreated advanced non-small cell lung cancer. 1 Nati Cancer Inst. (1993) 85:384–388.
   Google Scholar
• •Along with reference 28 the first Phase II data identifying the antitumour activity of paclitaxel in patients with advanced NSCLC.
   Google Scholar
• TAN V, HERRERA C, EINZROI Al et al.: Taxol is active as a3-hour or 24-hour infusion in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (1995) 14:366. Abstract 1122.
   Google Scholar
• MILLWARD MJ, BISHOP JF, FRIEDLANDER M et al.: PhaseII trial of a 3 h infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol. (1996) 14:142–148.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U, HECKMERY M, NEUHAUS R et al: PhaseII study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer (1995) 12 (Suppl. 2):S101–S106.
   Google Scholar
• ALBEROLA V, ROSELL R, GONZALEZ-LARRIBA JL et al.:Single agent taxol, 3-hour infusion in untreated advanced non-small cell lung cancer. Ann. Oncol (1995) 6\(Suppl. 3):49–52.
   Google Scholar
• SEKINE I, NISHIWAKI Y, WATANABE K et al.: Phase IIstudy of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin. Cancer Res. (1996) 2:941–946.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, THOMPSON DS, GRECO FA et al: Paclitaxel by one hour infusion: An active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. (1995) 13:1609–1614.
   PubMed Web of Science ®Google Scholar
• TESTER W, JIN PY, REARDEN DH et al.: Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer (1997) 79:724–729.
   PubMed Web of Science ®Google Scholar
• RANSON M, JAYSON G, PERKINS S et al. Single agent paclitaxel in non-small cell lung cancer: Single centre Phase II study using a 3-hour administration schedule. Semin. Oncol. (1997) 24 (Suppl. 12):12–16.
   Google Scholar
• AKERLEY W, CHOY H, SAFRAN H et al.: Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a Phase II trial. Semin. Oncol. (1997) 24 (Suppl. 12):10–12.
   Google Scholar
• •Promising preliminary data of an intensive weekly regimen of paclitaxel in advanced NSCLC.
   Google Scholar
• FURUSE K, NAKA N, TAKADA M et al: Phase II study of
   Google Scholar
• -hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. Oncology (1997) 54:298–303.
   PubMed Web of Science ®Google Scholar
• THATCHER N, RANSON M, ANDERSON H et al.: Phase III study of paclitaxel (taxol) versus best supportive care in inoperable non-small cell lung cancer. Eur. Soc. Med. Onc. (1998) XX:xxx Abst.
   Google Scholar
• AKERLEY W: Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin. Oncol. (1996) 23 (Suppl. 16):55–58.
   Google Scholar
• GEORGIADID MS, RUSSELL EK, GAZDAR AF, JOHNSONBE: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin. Cancer Res. (1997) 3:449–454.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL DI, OKANI 0, CORAK J et al.: Seven weekcontinuous infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a Phase I study. Semin. Oncol. (1997) 24 (Suppl. 12):96–100.
   Google Scholar
• ROWINSKY EK, CHARDBURY V, FORASTIERE AA et al.:Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony stimulating factor: Neuromuscular toxicity is dose limiting. J. Clin. Oncol (1993) 11:2010–2020.
   PubMed Web of Science ®Google Scholar
• BELLI L, LE CHEVALIER T, GOFFRIED M et al.: Phase I-IItrial of paclitaxel (Taxofi and cisplatin in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1995) 14:350. Abstract 1058.
   Google Scholar
• PIRKER R, KRAJNIK G, ZOCHHAUSER S et al.: Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. Oncol. (1995) 6:833–835.
   PubMed Web of Science ®Google Scholar
• KLATERSKY J, SCULIER JP: Dose finding study of paclitaxel (Taxo0 plus cisplatin in patients with non-small cell lung cancer. Lung Cancer (1995) 12:117–125.
   Web of Science ®Google Scholar
• VON PAWEL J, WAGNER H, NIEDERLE N et al: Phase IIstudy of paclitaxel and cisplatin in patients with-small cell lung cancer. Semin. Oncol. (1996) 23 (Suppl. 6):47–50.
   Google Scholar
• GEORGIADIS MS, SCHULER BS, BROWN JE et al.: Paclitaxel by 96 h continuous infusion in combination with cisplatin: A Phase I trial in patients with advanced lung cancer. J. Clin. Oncol. (1997) 15:735–743.
   PubMed Web of Science ®Google Scholar
• SORENSEN JB, WEDERVANG K, DOMORNOWSKY P: Preliminary results of a Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol (1997) 24 (Suppl. 12):18–20.
   Google Scholar
• HSU JW, HSU YJ, CHIANG CD: Preliminary result of Phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small cell lung cancer in Chinese patients. Am. J. Clin. Oncol (1998) 21:487–490.
   PubMed Web of Science ®Google Scholar
• GELMAN KA. Biweekly paclitaxel and cisplatin in breast and ovarian cancer. Semin. Oncol (1994) 21 (Suppl. 8):24–28.
   Google Scholar
• GEORGIADIS MS., BROWN JE, SCHULER BS et al.: Phase I study of a four day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer. Proc. Am. Soc. Clin. Oncol (1995)14:A1072.
   Google Scholar
• ROWINSKY EK, CITARDI MJ, NOE DA et al.: Sequence dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol (1993) 119:727–733.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, GILBERT MR, MCGUIRE WP et al.: Sequences of taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol (1991) 9:1692–1703.
   PubMed Web of Science ®Google Scholar
• BELANI CP: Paclitaxel, combinations with cisplatin or carboplatin in non-small cell lung cancer. In: Taxanes in Lung cancer Therapy. Johnson DH Klastersky J (Eds.), Macel Dekker, Inc. New York, USA (1998):141–158.
   Google Scholar
• BONOMI P, KIM K, KUSLER J, JOHNSON D: Cisplatin/etoposide vs. paclitaxel/cisplatin/GCSF vs. paclitaxel/cisplatin in non-small cell lung cancer Oncol. Hunting (1997) 11 (Suppl. 3):9–10.
   Google Scholar
• ••ECOG randomised trial which showed superior responserate and median survival for the two paclitaxel-containing arms compared to that seen with cisplatin + etoposide. A springboard to further randomised trials involving paclitaxel in combination with platinum compounds.
   Google Scholar
• GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organisa-tion for Research and Treatment of Cancer Lung cancer Cooperative Group. J. Clin. Oncol (1998) 16:2133–2141.
   Google Scholar
• ••EORTC randomised trial which though not demonstratingsurvival advantage for the paclitaxel-containing arm concluded that it offered better palliation than cisplatin + teniposide.
   Google Scholar
• ROWINSKY EK, BONOMI P, JIROUTEK M et al.: Pharma- studies of paclitaxel in ECOG 5592: A Phase III trial comparing etoposide plus cisplatin versus low dose paclitaxel plus cisplatin versus high dose paclitaxel plus cisplatin plus G-CSF in advanced-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:A450.
   Google Scholar
• BONOMI PD, FINKELSEIN DM, RUCKDESCHEL JC et al.:Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol (1989) 7:1602–1613.
   PubMed Web of Science ®Google Scholar
• LANGER CJ, LEIGHTON JC, COMIS RL et al: Paclitaxel andcarboplatin in combination in the treatment of advanced non-small cell lung cancer: a Phase II toxicity, response and survival analysis. J. Clin. Oncol. (1995) 13:1360–1370.
   Google Scholar
• JOHNSON DH, PAUL DM, HANDE KR et al.: Paclitaxel(taxol) plus carboplatin for advanced non-small cell lung cancer: preliminary results of a Vanderbilt University Phase II trial-LUN 46. Semin. Oncol (1995) 22\(Suppl. 9)30–33.
   Google Scholar
• BELANI CP, AISNER J, HIPONIA D et al.: Paclitaxel andcarboplatin with and without filgratim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. (1995) 22\(Suppl. 9):7–12.
   Google Scholar
• BUNN PA, KELLY K: A Phase I study of carboplatin andpaclitaxel in non small cell lung cancer: A University of Colorado Cancer Centre Study. Semin. Oncol (1995) 22(Suppl.
   Google Scholar
• ROWINSKY EK, FLOOD WA, SARTORIUS SE eta].: Phase Istudy of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin. Oncol. (1995) 22\(Suppl. 9):48–54.
   Google Scholar
• EVANS WK STEWARD DJ, TOMIAC E et al: Carboplatinand paclitaxel by one hour infusion for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1995) 14:374. Abstract 1156.
   Google Scholar
• NATALE RB: Preliminary results of a Phase I/II clinicaltrial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. (1996) 23 (Suppl. 16):51–54.
   Google Scholar
• STEPPERT C, BULTZINGSLOWEN F, WEISS J et al:.Polychemotherapy with carboplatin (CBDCA) and paclitaxel in advanced NSCLC- a Phase II study. Ann. Oncol. (1996) 7\(Suppl. 5):93.
   Google Scholar
• ROA V, CONNER A MITCHELL RB: Carboplatin and paclitaxel for chemotherapy naïve patients with advanced non-small cell lung cancer. Proc. Am. Soc. Oncol. (1996) 15:404. Abstract.
   Google Scholar
• LANGER CJ, MILLENSON M, ROSVOLD E et al.: Paclitaxel (1 h) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer, A Phase II study of the Fox Chase Cancer Centre and its network. Semin. Oncol. (1997) 24\(Suppl. 12):81–88.
   Google Scholar
• LANGER CJ, LEIGHTON JC COMIS RL et al.: Paclitaxel by 24 h or 1 h infusion in combination with carboplatin in advanced non-small cell lung cancer: The Fox Chase Cancer Centre experience. Semin. Oncol. (1995) 22\(Suppl. 9):18–29.
   Google Scholar
• DEVORE RF III, JAGASIS M, JOHNSON DH eta].: Paclitaxelby either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer; preliminary results comparing sequential Phase II trials. Semin. Oncol. (1997) 24\(Suppl. 12):27–29.
   Google Scholar
• CREAVEN PJ, RAGHAVAV D, PENYALA L et al.: Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin. Oncol. (1997) 24\(Suppl. 12):138–143.
   Google Scholar
• EVANS WK, EARLE CC, STEWART DJ et al: Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer (1997) 18:83–94.
   PubMed Web of Science ®Google Scholar
• ROYCHOWDHURY DF, DESAI P, ZHU Y-W: Paclitaxel (3-hour infusion) followed by carboplatin (24 h after paclitaxel) a Phase II study in advanced non-small cell lung cancer. Semin. Oncol. (1997) 24 (Suppl. 12)37–40.
   Google Scholar
• KOSMIDIS PA, MYLONAKIS N, FOUNTZILAS G et al: Paclitaxel and carboplatin in inoperable non-small cell lung cancer: a Phase II study. Ann. Oncol. (1997) 8:697–699.
   PubMed Web of Science ®Google Scholar
• HUIZING MT, GIACCONE G, VAN WARMERDAM LJ et al:Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose sequencing study in patients with non-small cell lung cancer. J. Gun. Oncol. (1997) 15:317–329.
   Web of Science ®Google Scholar
• KELLY K, PAN Z, MURPHY J et al.: A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. CLin. Cancer Res. (1997) 3:1117–1123.
   PubMed Web of Science ®Google Scholar
• GRECO FA, HAINSWORTH JD et al.: One-hour paclitaxel plus carboplatin for advanced no-small cell lung cancer. Oncology-Hunting (1998) 12\(Suppl. 2):71–73.
   Google Scholar
• RATANATHARATHORN V, JIRAJARUS M, SIRACHAINAN E et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): a preliminary study. J. Med. Assoc. Thai. (1998) 81:763–771.
   PubMedGoogle Scholar
• KOSMIDIS P, MYLONAKIS N, SKARLOS D et al.: Paclitaxel(175mg/m2) plus carboplatin versus paclitaxel (225mg/m2 plus carboplatin in inoperable non-small cell lung cancer: A randomised trial of the Hellenic Cooperative Oncology Group. Semin. Oncol. (1999) 26\(Suppl. 2):73. Abstract.
   Google Scholar
• KEARNS CM., BELANI CP ERKMEN K et al.: Reducedplatelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc. Am. Soc. Clin. Oncol (1995) 14:A364.
   Google Scholar
• OBASAJU CK, JOHNSON SW, ROGATKO A et al.: Evalua-tion of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin. Cancer Res. (1996) 2:549–552.
   PubMed Web of Science ®Google Scholar
• KEARNS CM, BELANI CP, ERKMEN K eta].: Pharmacoki-netics of paclitaxel and carboplatin in combination. Semin. Oncol (1995) 22\(Suppl. 12):1–4.
   Google Scholar
• SIDDIQUI N, BODDY AV, THOMAS HD et al.: A clinicaland pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer (1997) 75:287–294.
   PubMed Web of Science ®Google Scholar
• GEORGOULIAS V, KOUROUSIS C, KAKALYSIS S et al.:Second line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin. Oncol. (1997) 24\(Suppl. 12):61–66.
   Google Scholar
• HOFFMAN PC, MASTERS GA, DRINKARD LC et al: Ifosfa-mide plus paclitaxel in advanced non-small cell lung cancer:a Phase I study. Ann. Oncol. (1996) 7:314–316.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, LATREILLE J, CRUMP M et al.: Phase Istudy of paclitaxel (Taxol) and ifosfamide in previously treated patients with advanced non small cell lung cancer. Ann. Oncol. (1996) 7:311–313.
   PubMed Web of Science ®Google Scholar
• THONGPRASERT S: Phase II study of paclitaxel (Taxol)and ifosfamide (Holoxon) in inoperable non-small cell lung cancer. Lung Cancer (1998) 19:185–189.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, EISENHAUER E: Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. Semin. Oncol. (1998) 25(Suppl.
   Google Scholar
• VOKES EE, MASTERS GA, MAUER AM et al.: Ifosfamidebased three drug combination regimens in non-small cell lung cancer. Semin. Oncol. (1998) 25 (Suppl. 2):19–22.
   Google Scholar
• ZABIBONI A, MERIGGI F, RIZZI A et al: Paclitaxel, ifosfa-mide and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: preliminary results. Semin. Oncol. (1997) 24\(Suppl. 12):67–69.
   Google Scholar
• GRECO FA, BURRIS H, HAINSWORTH JD: Paclitaxel/carboplatin-based triplets in advanced lung cancer. Semin. Oncol (1999) 26\(Suppl. 2):75.
   Google Scholar
• VOKES EE, MAUER AM, HOFFMAN PC et al.: Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin. Oncol. (1999) 26\(Suppl. 2)76.
   Google Scholar
• SAUSE WT, SCOTT C, TAYLOR S et al.: Radiation TherapyOncology Group (RTOG) 88-08 and Eastern Coopera-tive Oncology Group (ECOG) 4588: Preliminary results of a Phase III trial in regionally advanced unresectable non-small cell lung cancer. J. Natl. Cancer Inst. (1995) 87:198–205.
   PubMed Web of Science ®Google Scholar
• •Early initial attempt to exploit the radiosensitisation actions of paclitaxel in locally advanced NSCLC and a spur to further studies.
   Google Scholar
• FRASCI G, COMELLA P, SCOPPA G et al.: Weeklypaclitaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer. J. Clin. Oncol. (1997) 15:1409–1417.
   PubMed Web of Science ®Google Scholar
• VOGT HG, MARTIN T, KOLOTAS C et al.: Simultaneouspaclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Semin Oncol (1997) 24\(Suppl. 12):101–105.
   Google Scholar
• SOCINSKI MA, CLARK JA, HALLE J et al: Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose escalating conformal radiotherapy in the treatment of locally advanced unresectable non-small cell lung cancer; preliminary report of a Phase I trial. Semin. Oncol (1997) 24\(Suppl. 12):117–122.
   Google Scholar
• LAU DH, RYU JK, GANDARA DR et al.: Twice weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin. Oncol (1997) 24\(Suppl. 12):106–109.
   Google Scholar
• CHOY H, DEVORE RF, HANDE KR et al.: Preliminary analysis of a Phase II study of paclitaxel carboplatin and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin. Oncol (1997) 24\(Suppl. 12):21–26.
   Google Scholar
• ROSENTHAL DI, OKANI 0, CORAK J et al.: Seven week continuous infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin. Oncol (1997) 24 (Suppl. 12)96–100.
   Google Scholar
• LANGER CJ, MOVSAS B, HUDES R et al.: Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung carcinoma; report of Fox Chase Cancer Center study 94–001. Semin. Oncol (1997) 24\(Suppl. 12):89–95.
   Google Scholar
• KIRKBRIDE P, GELMON K, EISENHAUER E, FISHER B, DULUDE H: A Phase I/II study of paclitaxel (taxol) and concurrent radiotherapy in advanced non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39:1107–1111.
   PubMed Web of Science ®Google Scholar
• CHOY H, AKERLEY W, DEVORE R: Paclitaxel, carboplatin and radiation therapy for non-small cell lung cancer. Oncol-Huntingt. (1998) 12 (Suppl. 2):80–86.
   Google Scholar
• ISOKANGAS OP, JOENSUU H, HALME M, JEKUNEN A MATTSON K: Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III non-small cell lung cancer. Lung Cancer (1998) 20:127–133.
   PubMed Web of Science ®Google Scholar
• CHOY H, SAFRAN H, AKERLEYW GRAZIANO SL, BOGART JA, COLE BF: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res. (1998) 4:1931–1936.
   PubMed Web of Science ®Google Scholar
• BELANI CP: Incorporation of paclitaxel and carboplatin in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Oncol (1999) 26 (Suppl. 2):44–54.
   Google Scholar
• CHOY H, AKERLEY W, DEVORE RF: Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer. Semin. Oncol. (1999) 26\(Suppl. 2):36–43. Ransont & Nicholas Thatcher for correspondence Department of Medical Oncology, Christie Hospital NHS Trust, Road, Manchester, M20 4BX, UK.: +44 161 446 3606; Fax: +44 161 446 3299;: [email protected]
   Google Scholar